Ad comm meeting approaches for Durata drug Anti-Infective Drugs Advisory Committee meets on Monday to review Durata Therapeutics' (DRTX) antibacterial Dalvance (dalbavancin) NDA. PDUFA date is May 26. Consensus total revenue estimates for 2014 and 2015 are $16.3M and $67.2M, respectively. briefing docs..http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm385739.htm